Company / Total Debt
MADRIGAL PHARMACEUTICALS, INC. Total Debt History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$339.9M
FY2025
5-year range
$0 / $339.9M
FY2021-FY2025
Trend
+189.1%
vs FY2024
Sector context
#35 of 83
Health Care
What the data says
At $340M, MADRIGAL PHARMACEUTICALS, INC.'s total debt ranks #49 of 83 in the Health Care sector. Total Debt has increased for 4 consecutive years, from $0 in FY2021 to $340M in FY2025.
Based on SEC 10-K filings.
$340M in FY2025 with a 3-year CAGR of +90.3%.
Increased from $115M to $340M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +90.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#49 of 83 in Health CareTop 58% of 83This company $339.9M Sector average $6.2B
▼
-94.5% below sector average
Key checks
Key Insights
- MADRIGAL PHARMACEUTICALS, INC.'s total debt has grown for 3 consecutive years.
- 3-year CAGR of +90.3%, indicating consistent growth.
- In FY2025, total debt increased 189.1% year-over-year.
- Ranks #35 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $339.9M | +189.1% |
| FY2024 | $117.6M | +1.8% |
| FY2023 | $115.5M | +134.3% |
| FY2022 | $49.3M | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026